Efficacy of Suhexiang pill combined with galantamine hydrobromide in treating patients with post-stroke cognitive impairment
WANG Linlin
ZHUANG Chanjuan
LI Yixuan
SUN Liying
WANG Bilian
Abstract：Objective To investigate the clinical efficacy of Suhexiang pill combined with galantamine hydrobromide in treating post-stroke cognitive impairment(PSCI).Methods A total of 136 PSCI patients admitted to Shidong Hospital of Shanghai Yangpu District from January 2024 to April 2025 were enrolled in this prospective study.They were randomly assigned to the observation group(68 cases treated with Suhexiang pill combined with galantamine hydrobromide)and the control group(68 cases treated with galantamine hydrobromide alone).The clinical efficacy,serum inflammatory cytokine levels,neurological deficit severity,drug safety,cognitive function,and daily living ability before treatment and after 12 weeks of intervention were compared between the two groups.Results After 12 weeks of treatment,the National Institutes of Health Stroke Scale scores in the control group and the observation group decreased significantly compared with baseline(both P＜0.001),and the score in the observation group(4.76±1.56)was lower than that in the control group(6.04±1.89)(t=4.312,P＜0.001).After 12 weeks of treatment,the scores of the Mini-Mental State Examination,Activities of Daily Living,and Montreal Cognitive Assessment in the control group and the observation group showed significant improvement compared to those before treatment(all P＜0.001).The above indicators in the observation group((25.93±2.08)points,(70.96±9.12)points,(31.59±5.75)points)were higher than those in the control group((23.74±1.91)points,(64.87±7.83)points,(27.04±5.18)points)(t=6.389,4.176,4.844,all P＜0.05).After 12 weeks of treatment,the total effective rate in the observation group was higher than that in the control group(92.65%(63/68)vs 79.41%(54/68),χ2=4.955,P＜0.05).Serum interleukin-6(IL-6)and C-reactive protein(CRP)levels were significantly reduced in the control group and the observation group compared to those before treatment(all P＜0.001).Specifically,the observation group showed lower IL-6(123.65±13.69)ng/L and CRP(5.04±1.22)mg/L levels than the control group((149.87±14.82)ng/L and(6.26±1.68)mg/L)(t=10.719,4.815,both P＜0.001).There was no statistically significant difference in the incidence of adverse reactions between the two groups(7.35%(5/68)vs 14.71%(10/68),χ2=1.873,P＞0.05).Conclusion The combination of Suhexiang pill and galantamine hydrobromide in the treatment of PSCI can significantly improve patients'neurological function and cognitive abili-ties,enhance their quality of life and clinical efficacy,effectively inhibit inflammatory responses,and demonstrate good safety.
Keywords：Suhexiang pillgalantamine hydrobromidestrokecognitive impairmentclinical efficacy
Publication Date：2025-12-25
Online Publishing Date：2026-01-07(First online date of this platform, not the publication date of the document)
Pages：5( 1584-1588 )